about
Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosisBiomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesis.B cell depletion may lead to normalization of anti-platelet, anti-erythrocyte and antiphospholipid antibodies in systemic lupus erythematosus.Toll-like receptor 4 mediates endothelial cell activation through NF-κB but is not associated with endothelial dysfunction in patients with rheumatoid arthritisPorphyromonas gingivalis and the pathogenesis of rheumatoid arthritis: analysis of various compartments including the synovial tissue.B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial.PTPN22 1858C>T polymorphism distribution in Europe and association with rheumatoid arthritis: case-control study and meta-analysis.B cells in systemic sclerosis: a possible target for therapy.Memory B cell subsets and plasmablasts are lower in early than in long-standing rheumatoid arthritis.Interleukin-1β and interleukin-6 in arthritis animal models: roles in the early phase of transition from acute to chronic inflammation and relevance for human rheumatoid arthritisObesity as a risk and severity factor in rheumatic diseases (autoimmune chronic inflammatory diseases).Very early rheumatoid arthritis is the major predictor of major outcomes: clinical ACR remission and radiographic non-progression.B-cell subsets in the joint compartments of seropositive and seronegative rheumatoid arthritis (RA) and No-RA arthritides express memory markers and ZAP70 and characterize the aggregate pattern irrespectively of the autoantibody status.Polymorphism of immunoglobulin enhancer element HS1,2A: allele *2 associates with systemic sclerosis. Comparison with HLA-DR and DQ allele frequencyPharmacogenetics/pharmacogenomics and antirheumatic drugs in rheumatology.Collagen Specific T-Cell Repertoire and HLA-DR Alleles: Biomarkers of Active Refractory Rheumatoid ArthritisPharmacogenetic of antirheumatic treatments: clinical implications.Tapering and discontinuation of TNF-α blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission.Infections, B cell receptor activation and autoimmunity: different check-point impairments lead to autoimmunity, clonal B cell expansion and fibrosis in different immunological settings.Allele *2 of the HS1,2A enhancer of the Ig regulatory region associates with rheumatoid arthritis.MicroRNA-155 influences B-cell function through PU.1 in rheumatoid arthritis.Thymosin β4 and β10 in Sjögren's syndrome: saliva proteomics and minor salivary glands expression.Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis.Biomolecular features of inflammation in obese rheumatoid arthritis patients: management considerations.Do we need to apply a T2T strategy even in ACPA-negative early rheumatoid arthritis? YESSynovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?Erratum to: Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis.Could we use a lower dose of rituximab to treat rheumatoid arthritis in clinical practice: pros and cons?Analysis of response to infliximab in ankylosing spondylitis according to the axial and/or peripheral involvement: autoantibodies and drop outs are more frequent in the peripheral subset.Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis.Body weight, gender and response to TNF-α blockers in axial spondyloarthritis.Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis.Weight Loss, The Obesity Paradox in Rheumatoid Arthritis: Is It a Paradox? Comment on the Article by Baker et al.ZAP-70+ B cell subset influences response to B cell depletion therapy and early repopulation in rheumatoid arthritis.A vascular endothelial growth factor deficiency characterises scleroderma lung disease.Synovial B cells of rheumatoid arthritis express ZAP-70 which increases the survival and correlates with the inflammatory and autoimmune phenotype.Synovial fluid-derived T helper 17 cells correlate with inflammatory activity in arthritis, irrespectively of diagnosis.The role of high-mobility group box protein 1 in collagen antibody-induced arthritis is dependent on vascular endothelial growth factor.Is Citrullination Required for the Presence of Restricted Clonotypes Reacting With Type II Collagen? Comment on the Article by Chemin et alPolymorphisms of the IgH enhancer HS1.2 and risk of systemic lupus erythematosus
P50
Q24814170-FE970B47-2765-43E8-B2A2-D35168A2771FQ31078960-5C76C67A-A552-417E-818B-9DFAD4BC661DQ33363720-C926D1FC-4FE9-4355-A625-1E37829DA6A9Q33740199-575803C3-6529-4E1D-8CC3-4CD79D3A8CD1Q33766304-E08E25F3-EC43-4CD2-B24D-8409FA09CB38Q33923359-EFBA56EC-2EBD-4443-904C-51D7EF398684Q34031304-67304FA5-756B-44A6-BC04-50A944DFFD3EQ34183002-7D1AF6E7-E283-4A78-942C-4BD5CF946664Q34208191-094592EF-CFDF-4234-A015-5589D7F304C9Q34274249-7D47DDBF-C970-490F-B7C9-40A8501C2311Q34488394-8D0E6C69-7C30-4A2F-9ECA-6E181EA21777Q35012150-12B68F8E-8AA7-446C-A7D9-014F53FA6169Q35286950-573A1912-51C4-44C3-BB16-741C849C90CDQ35954658-73B67EE0-C2DA-42AD-890E-88FDF47C8E91Q35976402-44DA041C-F319-40DA-8625-564DD7548E24Q36437722-0318A1EE-6101-4C10-9686-00F08547906CQ36480014-2482C52C-0589-4D68-AA6C-409FA0457F50Q36543127-FBEC7D36-220C-4BCE-A941-92BF8D356BE4Q37012523-BE26BBF3-BBF3-42E1-8A32-D49FB259A5B4Q37079254-7FE7C004-39E3-4050-8EA9-1F431B6E82D7Q37315021-17670778-1646-4F84-85EB-1B88A6668CA4Q37316072-2444B761-D252-42EE-8599-CA132C472621Q37498738-F4B3C111-DA79-46D5-8C66-F98C6C5CC820Q38763702-63041E65-E222-411F-9705-1B79042762A6Q39834837-0130436D-4644-4E28-A87E-9940466492ECQ41146155-7132377B-952C-42FC-A576-E4CCC8965985Q42328583-B75347E1-57CE-4523-B8A3-943437445131Q42745125-0E937138-2BB0-4229-B9A0-A224024DAF17Q42845094-9E61454F-047D-4A9F-A46F-8FB81EA34051Q43868814-B0FE6D70-8321-4C33-92D6-43ED900123B0Q44115144-2F4F93DF-7771-4683-8FF6-687E11E7C870Q44137392-9933A871-C56C-475C-AD04-896BB7AB2758Q47348257-F4B31818-A544-4EFA-86AB-EF721861C1C0Q50937787-4FBAB55D-A766-4592-A5BE-4FFFA801DC4CQ54320082-CDED55E7-3EE8-4D27-98AE-2EF54861D4C3Q54499509-C46280C1-46C3-40F2-A2C6-A81DC9CDE3C8Q54634777-F585B1D1-4C02-4A3B-A9A7-FEB1D4B28812Q55034259-25D6BA3B-BAD7-4B90-9E14-7D1ECA91B460Q57752907-8CA37E40-A940-405B-B226-2CCCBB1A866CQ57753297-F8EE8D97-C7D6-4493-87DC-F23BB3DE3598
P50
description
hulumtuese
@sq
researcher
@en
researcher
@en-gb
wetenschapper
@nl
հետազոտող
@hy
name
Barbara Tolusso
@ast
Barbara Tolusso
@en
Barbara Tolusso
@en-gb
Barbara Tolusso
@es
Barbara Tolusso
@nl
Barbara Tolusso
@sl
type
label
Barbara Tolusso
@ast
Barbara Tolusso
@en
Barbara Tolusso
@en-gb
Barbara Tolusso
@es
Barbara Tolusso
@nl
Barbara Tolusso
@sl
prefLabel
Barbara Tolusso
@ast
Barbara Tolusso
@en
Barbara Tolusso
@en-gb
Barbara Tolusso
@es
Barbara Tolusso
@nl
Barbara Tolusso
@sl
P106
P1153
6506472108
P21
P31
P496
0000-0002-9108-6609